MA51288A - Analogues d'incrétine et leurs utilisations - Google Patents
Analogues d'incrétine et leurs utilisationsInfo
- Publication number
- MA51288A MA51288A MA051288A MA51288A MA51288A MA 51288 A MA51288 A MA 51288A MA 051288 A MA051288 A MA 051288A MA 51288 A MA51288 A MA 51288A MA 51288 A MA51288 A MA 51288A
- Authority
- MA
- Morocco
- Prior art keywords
- incretin
- analogues
- incretin analogues
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/605—Glucagons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/26—Glucagons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/542—Carboxylic acids, e.g. a fatty acid or an amino acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Epidemiology (AREA)
- Biochemistry (AREA)
- Toxicology (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Child & Adolescent Psychology (AREA)
- Emergency Medicine (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Plant Substances (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicinal Preparation (AREA)
- Measurement And Recording Of Electrical Phenomena And Electrical Characteristics Of The Living Body (AREA)
- Details Of Garments (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762608613P | 2017-12-21 | 2017-12-21 | |
| PCT/US2018/065663 WO2019125938A1 (fr) | 2017-12-21 | 2018-12-14 | Analogues d'incrétine et leurs utilisations |
| EP18830618.7A EP3727426B1 (fr) | 2017-12-21 | 2018-12-14 | Analogues d'incrétine et leurs utilisations |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MA51288A true MA51288A (fr) | 2021-03-31 |
| MA51288B1 MA51288B1 (fr) | 2026-02-27 |
Family
ID=65003519
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA51288A MA51288B1 (fr) | 2017-12-21 | 2018-12-14 | Analogues d'incrétine et leurs utilisations |
Country Status (36)
| Country | Link |
|---|---|
| US (4) | US11542313B2 (fr) |
| EP (2) | EP3727426B1 (fr) |
| JP (3) | JP6961838B2 (fr) |
| KR (2) | KR102444783B1 (fr) |
| CN (1) | CN111491658B (fr) |
| AR (1) | AR113486A1 (fr) |
| AU (1) | AU2018388962B2 (fr) |
| BR (1) | BR112020010244A2 (fr) |
| CA (1) | CA3084005C (fr) |
| CL (1) | CL2020001635A1 (fr) |
| CO (1) | CO2020006255A2 (fr) |
| CR (1) | CR20200255A (fr) |
| DK (1) | DK3727426T3 (fr) |
| DO (1) | DOP2020000123A (fr) |
| EA (1) | EA202091290A1 (fr) |
| EC (1) | ECSP20032650A (fr) |
| ES (1) | ES3061179T3 (fr) |
| FI (1) | FI3727426T3 (fr) |
| HR (1) | HRP20260186T1 (fr) |
| IL (2) | IL325353A (fr) |
| JO (1) | JOP20200137B1 (fr) |
| LT (1) | LT3727426T (fr) |
| MA (1) | MA51288B1 (fr) |
| MD (1) | MD3727426T2 (fr) |
| MX (2) | MX2020006548A (fr) |
| MY (1) | MY199143A (fr) |
| PE (2) | PE20210162A1 (fr) |
| PH (1) | PH12020551025A1 (fr) |
| PL (1) | PL3727426T3 (fr) |
| PT (1) | PT3727426T (fr) |
| RS (1) | RS67748B1 (fr) |
| SG (1) | SG11202005606VA (fr) |
| SI (1) | SI3727426T1 (fr) |
| TW (3) | TWI912614B (fr) |
| UA (1) | UA129012C2 (fr) |
| WO (1) | WO2019125938A1 (fr) |
Families Citing this family (42)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR113486A1 (es) * | 2017-12-21 | 2020-05-06 | Lilly Co Eli | Análogos de incretina y sus usos |
| EP3882263A4 (fr) * | 2018-11-12 | 2022-08-31 | Tianjin Institute Of Pharmaceutical Research Co., Ltd. | Peptide dérivé du glucagon et utilisation associée |
| KR102812908B1 (ko) * | 2019-08-19 | 2025-05-28 | 일라이 릴리 앤드 캄파니 | 인크레틴 유사체의 제조 방법 |
| US20250346647A2 (en) * | 2019-12-03 | 2025-11-13 | Antag Therapeutics Aps | Optimized GIP Peptide Analogues |
| AR120714A1 (es) * | 2019-12-18 | 2022-03-09 | Lilly Co Eli | Análogos de incretina y sus usos |
| CN115335395A (zh) * | 2020-03-25 | 2022-11-11 | 武田药品工业株式会社 | Gip受体激动剂肽化合物的qd给药及其用途 |
| US20230391845A1 (en) | 2020-10-30 | 2023-12-07 | Novo Nordisk A/S | Glp-1, gip and glucagon receptor triple agonists |
| CN114685642B (zh) * | 2020-12-29 | 2024-03-29 | 浙江和泽医药科技股份有限公司 | 一种肠促胰岛素类似物药学上可接受盐及制备方法和用途 |
| CA3204051A1 (fr) | 2021-01-20 | 2022-07-28 | Brian Lian | Compositions et procedes pour le traitement de troubles metaboliques et hepatiques |
| TWI837615B (zh) * | 2021-03-23 | 2024-04-01 | 美商美國禮來大藥廠 | 含腸促胰島素(incretin)類似物之組合物及其用途 |
| WO2022247701A1 (fr) | 2021-05-26 | 2022-12-01 | 联邦生物科技(珠海横琴)有限公司 | Multi-agoniste et son utilisation |
| WO2022268029A1 (fr) * | 2021-06-21 | 2022-12-29 | 广东东阳光药业有限公司 | Agoniste triple pour récepteurs glp-1, gcg et gip |
| CA3223313A1 (fr) | 2021-06-23 | 2022-12-29 | Eli Lilly And Company | Methodes d'utilisation et compositions comprenant un analogue d'incretine |
| JP7642830B2 (ja) | 2021-09-15 | 2025-03-10 | バイキング・セラピューティクス・インコーポレイテッド | 代謝及び肝臓障害の処置のための組成物及び方法 |
| TWI828434B (zh) * | 2021-11-19 | 2024-01-01 | 大陸商南京明德新藥研發有限公司 | 釘合肽及其應用 |
| AU2022392980B2 (en) * | 2021-11-19 | 2025-12-18 | Jiangsu Deyuan Pharmaceutical Co., Ltd. | Stapled peptide and use thereof |
| CN116162147B (zh) * | 2021-11-24 | 2023-10-03 | 成都奥达生物科技有限公司 | 一种长效胰岛素类似物 |
| CN114957387B (zh) * | 2022-05-18 | 2023-06-20 | 华南理工大学 | 一种具有降血糖作用的巴旦木多肽及其制备方法与应用 |
| JP2025530743A (ja) | 2022-08-29 | 2025-09-17 | イーライ リリー アンド カンパニー | 経口投与のための組成物 |
| AU2023348864A1 (en) * | 2022-09-28 | 2025-03-20 | Sunshine Lake Pharma Co., Ltd. | Glp-1/gcg/gip triple-receptor agonist and use thereof |
| IL320036A (en) * | 2022-10-05 | 2025-06-01 | Lilly Co Eli | Peptides for incretin synthesis |
| KR20250110330A (ko) * | 2022-11-21 | 2025-07-18 | 일라이 릴리 앤드 캄파니 | Gip/glp1 이중 효능제의 제조 방법 |
| JP2026502943A (ja) | 2022-12-30 | 2026-01-27 | アルギファルマ エーエス | 経口投与されるポリペプチド治療剤の全身バイオアベイラビリティを高める組成物および方法 |
| US20240270821A1 (en) | 2023-01-31 | 2024-08-15 | Eli Lilly And Company | Gip/glp1/gcg tri-receptor agonists and uses thereof |
| CN118684758A (zh) * | 2023-03-23 | 2024-09-24 | 上海民为生物技术有限公司 | 肠促胰岛素类似物及其应用 |
| WO2024213022A1 (fr) * | 2023-04-11 | 2024-10-17 | 上海多米瑞生物技术有限公司 | Analogues d'incrétine et leur procédé de préparation, et utilisation |
| KR20260022948A (ko) * | 2023-06-09 | 2026-02-20 | 썬 파마슈티컬 인더스트리스 리미티드 | Glp-1/gip 이중 수용체 작용제, glp-1/gcg 이중 수용체 작용제, 및 glp-1/gip/gcg 삼중 수용체 작용제 |
| KR20240176455A (ko) | 2023-06-15 | 2024-12-24 | 노보 노르디스크 에이/에스 | 시클로덱스트린을 포함하는 약학적 제형 |
| CN117024528B (zh) * | 2023-07-07 | 2024-03-22 | 杭州信海医药科技有限公司 | 一种Retatrutide的制备方法 |
| AU2024291989A1 (en) | 2023-07-14 | 2026-01-15 | Jiangsu Hengrui Pharmaceuticals Co., Ltd. | Glp-1, gip and gcg receptor triagonist and use thereof |
| WO2025087353A1 (fr) * | 2023-10-26 | 2025-05-01 | 齐鲁制药有限公司 | Polypeptide présentant une activité multi-agoniste et son utilisation |
| CN120349393A (zh) * | 2023-11-06 | 2025-07-22 | 成都奥达生物科技有限公司 | 一种三激动剂化合物 |
| WO2025162423A1 (fr) * | 2024-02-02 | 2025-08-07 | 杭州先为达生物科技股份有限公司 | Triagoniste pour glp-1r, gipr et gcgr |
| WO2025264776A1 (fr) * | 2024-06-21 | 2025-12-26 | Neurocrine Biosciences, Inc. | Peptides chimiquement modifiés et leur utilisation |
| WO2025264809A1 (fr) * | 2024-06-21 | 2025-12-26 | Neurocrine Biosciences, Inc. | Peptides chimiquement modifiés et leur utilisation |
| WO2025264785A1 (fr) * | 2024-06-21 | 2025-12-26 | Neurocrine Biosciences, Inc. | Peptides chimiquement modifiés et leur utilisation |
| CN119978101B (zh) * | 2024-07-30 | 2025-10-10 | 四川普康药业有限公司 | 多肽化合物及其应用 |
| WO2026059846A1 (fr) | 2024-09-13 | 2026-03-19 | Eli Lilly And Company | Timbre à micro-aiguilles solubles pour administration transdermique d'un peptide |
| WO2026073030A1 (fr) | 2024-09-27 | 2026-04-02 | Carmot Therapeutics Inc. | Polythérapie à base d'analogues de peptide tyrosine-tyrosine (pyy) et d'agonistes de glp-1r |
| CN119823233A (zh) * | 2025-03-18 | 2025-04-15 | 杭州思诺达医药科技有限责任公司 | 瑞他鲁肽的合成方法及瑞他鲁肽 |
| CN120189527B (zh) * | 2025-05-27 | 2026-04-03 | 广州富肽生物有限公司 | 一种多肽与抗体Fc片段的偶联物、药物组合物及其用途 |
| CN120623312B (zh) * | 2025-06-26 | 2026-01-23 | 乐普健糖药业(重庆)有限公司 | Glp-1、gip、gcg三重受体激动剂及其制备方法和应用 |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102105159B (zh) * | 2008-06-17 | 2015-07-08 | 印第安纳大学研究及科技有限公司 | 基于gip的混合激动剂用于治疗代谢紊乱和肥胖症 |
| CN104127880A (zh) | 2009-03-27 | 2014-11-05 | 葛兰素集团有限公司 | 药用融合体和缀合物 |
| US20130157953A1 (en) * | 2010-01-20 | 2013-06-20 | Zealand Pharma A/S | Treatment of cardiac conditions |
| AR080592A1 (es) * | 2010-03-26 | 2012-04-18 | Lilly Co Eli | Peptido con actividad para el gip-r y glp-1-r, formulacion famaceutica que lo comprende, su uso para preparar un medicamento util para el tratamiento de diabetes mellitus y para inducir la perdida de peso |
| WO2012153196A2 (fr) * | 2011-05-10 | 2012-11-15 | Zealand Pharma A/S | Composés sélectifs pour une signalisation d'agonistes doubles de glu-glp1 |
| AR092873A1 (es) | 2012-09-26 | 2015-05-06 | Cadila Healthcare Ltd | Peptidos como agonistas triples de los receptores de gip, glp-1 y glugagon |
| WO2015067715A2 (fr) | 2013-11-06 | 2015-05-14 | Zealand Pharma A/S | Composés agonistes doubles de gip et glp-1 et procédés associés |
| CN105829339B (zh) * | 2013-11-06 | 2021-03-12 | 西兰制药公司 | 胰高血糖素-glp-1-gip三重激动剂化合物 |
| TWI582109B (zh) * | 2015-01-09 | 2017-05-11 | 美國禮來大藥廠 | Ｇｉｐ及ｇｌｐ－１共促效劑化合物 |
| WO2016198624A1 (fr) | 2015-06-12 | 2016-12-15 | Sanofi | Dérivés d'exendine 4 utilisés en tant qu'agonistes trigonaux des récepteurs du glp-1/glucagon/gip |
| TWI700291B (zh) * | 2015-06-22 | 2020-08-01 | 美國禮來大藥廠 | 升糖素及glp-1共激動劑化合物 |
| TWI622596B (zh) * | 2015-10-26 | 2018-05-01 | 美國禮來大藥廠 | 升糖素受體促效劑 |
| SG11201805586SA (en) | 2015-12-31 | 2018-07-30 | Hanmi Pharmaceutical Co Ltd | Triple glucagon/glp-1/gip receptor agonist |
| EP3217027A1 (fr) | 2016-03-08 | 2017-09-13 | HILTI Aktiengesellschaft | Élement de revetement large destine a entourer une tige d'ancrage |
| AR113486A1 (es) * | 2017-12-21 | 2020-05-06 | Lilly Co Eli | Análogos de incretina y sus usos |
| TWI767095B (zh) * | 2017-12-21 | 2022-06-11 | 美商美國禮來大藥廠 | 腸促胰島素(incretin)類似物及其用途 |
| CN119499352A (zh) * | 2018-07-23 | 2025-02-25 | 伊莱利利公司 | 使用gip/glp1共激动剂用于糖尿病的方法 |
| KR20240051304A (ko) * | 2018-07-23 | 2024-04-19 | 일라이 릴리 앤드 캄파니 | Gip/glp1 공효능제 화합물 |
| AR119471A1 (es) * | 2019-08-01 | 2021-12-22 | Lilly Co Eli | Compuestos agonistas de gipr |
| AR120714A1 (es) * | 2019-12-18 | 2022-03-09 | Lilly Co Eli | Análogos de incretina y sus usos |
| IL294955A (en) * | 2020-01-23 | 2022-09-01 | Lilly Co Eli | Cobalt-agonist gip/glp1 compounds |
| US20240270821A1 (en) * | 2023-01-31 | 2024-08-15 | Eli Lilly And Company | Gip/glp1/gcg tri-receptor agonists and uses thereof |
-
2018
- 2018-12-05 AR ARP180103560A patent/AR113486A1/es unknown
- 2018-12-05 TW TW112124080A patent/TWI912614B/zh active
- 2018-12-05 TW TW107143624A patent/TWI744579B/zh active
- 2018-12-05 TW TW110136047A patent/TWI809515B/zh active
- 2018-12-14 PE PE2020000802A patent/PE20210162A1/es unknown
- 2018-12-14 WO PCT/US2018/065663 patent/WO2019125938A1/fr not_active Ceased
- 2018-12-14 CN CN201880081212.3A patent/CN111491658B/zh active Active
- 2018-12-14 HR HRP20260186TT patent/HRP20260186T1/hr unknown
- 2018-12-14 KR KR1020207017387A patent/KR102444783B1/ko active Active
- 2018-12-14 MA MA51288A patent/MA51288B1/fr unknown
- 2018-12-14 ES ES18830618T patent/ES3061179T3/es active Active
- 2018-12-14 EA EA202091290A patent/EA202091290A1/ru unknown
- 2018-12-14 RS RS20260172A patent/RS67748B1/sr unknown
- 2018-12-14 KR KR1020227031761A patent/KR102622642B1/ko active Active
- 2018-12-14 SI SI201831298T patent/SI3727426T1/sl unknown
- 2018-12-14 MD MDE20201098T patent/MD3727426T2/ro unknown
- 2018-12-14 PE PE2025000913A patent/PE20251598A1/es unknown
- 2018-12-14 IL IL325353A patent/IL325353A/en unknown
- 2018-12-14 FI FIEP18830618.7T patent/FI3727426T3/fi active
- 2018-12-14 EP EP18830618.7A patent/EP3727426B1/fr active Active
- 2018-12-14 PL PL18830618.7T patent/PL3727426T3/pl unknown
- 2018-12-14 US US16/768,960 patent/US11542313B2/en active Active
- 2018-12-14 DK DK18830618.7T patent/DK3727426T3/da active
- 2018-12-14 MY MYPI2020003205A patent/MY199143A/en unknown
- 2018-12-14 AU AU2018388962A patent/AU2018388962B2/en active Active
- 2018-12-14 EP EP25217077.4A patent/EP4691555A3/fr active Pending
- 2018-12-14 JP JP2020551786A patent/JP6961838B2/ja active Active
- 2018-12-14 UA UAA202002925A patent/UA129012C2/uk unknown
- 2018-12-14 CA CA3084005A patent/CA3084005C/fr active Active
- 2018-12-14 SG SG11202005606VA patent/SG11202005606VA/en unknown
- 2018-12-14 PT PT188306187T patent/PT3727426T/pt unknown
- 2018-12-14 BR BR112020010244-0A patent/BR112020010244A2/pt unknown
- 2018-12-14 CR CR20200255A patent/CR20200255A/es unknown
- 2018-12-14 MX MX2020006548A patent/MX2020006548A/es unknown
- 2018-12-14 LT LTEPPCT/US2018/065663T patent/LT3727426T/lt unknown
-
2020
- 2020-05-22 CO CONC2020/0006255A patent/CO2020006255A2/es unknown
- 2020-06-02 JO JOJO/P/2020/0137A patent/JOP20200137B1/ar active
- 2020-06-17 CL CL2020001635A patent/CL2020001635A1/es unknown
- 2020-06-17 IL IL275468A patent/IL275468B1/en unknown
- 2020-06-17 PH PH12020551025A patent/PH12020551025A1/en unknown
- 2020-06-17 DO DO2020000123A patent/DOP2020000123A/es unknown
- 2020-06-19 EC ECSENADI202032650A patent/ECSP20032650A/es unknown
- 2020-07-13 MX MX2024010201A patent/MX2024010201A/es unknown
-
2021
- 2021-10-13 JP JP2021168050A patent/JP7658877B2/ja active Active
-
2022
- 2022-11-21 US US18/057,398 patent/US12365716B2/en active Active
-
2024
- 2024-09-23 US US18/893,357 patent/US12371465B2/en active Active
-
2025
- 2025-02-26 JP JP2025029445A patent/JP2025093970A/ja active Pending
- 2025-06-23 US US19/245,761 patent/US20250313605A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA51288A (fr) | Analogues d'incrétine et leurs utilisations | |
| MA51287A (fr) | Analogues d'incrétine et leurs utilisations | |
| EP3817822A4 (fr) | Agents de dégradation de protéines et leurs utilisations | |
| MA50618A (fr) | Polyrhérapies et leurs utilisations | |
| EP3749315A4 (fr) | Raltitrexed alpha-polyglutamaté et utilisations associées | |
| EP3749318A4 (fr) | Raltitrexed gamma-polyglutamaté et utilisations associées | |
| EP3471727A4 (fr) | Inhibiteurs de cxcr4 et leurs utilisations | |
| EP3472129A4 (fr) | Inhibiteurs de cxcr4 et leurs utilisations | |
| EP3600273A4 (fr) | Inhibiteurs de cd73 et leurs utilisations | |
| EP3749314A4 (fr) | Méthotrexate alpha-polyglutamaté et utilisations associées | |
| EP3445365A4 (fr) | Inhibiteurs d'ezh2 et leurs utilisations | |
| EP3383916A4 (fr) | Anticorps anti-cd73 et leurs utilisations | |
| EP3504243A4 (fr) | Anticorps anti-tim-3 et leurs utilisations | |
| EP3389702A4 (fr) | Anticorps anti-lag-3 et leurs utilisations | |
| EP3413816A4 (fr) | Compositions hydratantes et utilisations associées | |
| EP3426288A4 (fr) | Anticorps anti-pacap et leurs utilisations | |
| EP3344275A4 (fr) | Macrocycles peptidomimétiques et leurs utilisations | |
| EP3790861A4 (fr) | Compositions sénolytiques et utilisations associées | |
| MA42622A (fr) | Agents de liaison à tigit et leurs utilisations | |
| MA46704A (fr) | Anticorps anti-pyroglutamate- amyloïde-beta et leurs utilisations | |
| EP2968443A4 (fr) | Analogues d'hepcidine et leurs utilisations | |
| EP3439741A4 (fr) | Antagonistes d'alk7 et leurs utilisations | |
| EP3294318A4 (fr) | Macrocycles peptidomimétiques et leurs utilisations | |
| EP3283517A4 (fr) | Anticorps anti-pacap et leurs utilisations | |
| EP3471726A4 (fr) | Inhibiteurs de cxcr4 et leurs utilisations |